Jee Youn Oh1, Young Seok Lee1, Kyung Hoon Min1, Gyu Young Hur1, Sung Yong Lee1, Kyung Ho Kang1, Chin Kook Rhee2, Seoung Ju Park3, Jae Jeong Shim1. 1. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. 2. Division of Allergy and Pulmonary Medicine, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea. 3. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, Republic of Korea.
Abstract
BACKGROUND: Patients with tuberculosis-destroyed lungs (TDLs), with airflow limitation, have clinical characteristics similar to those of patients with chronic obstructive pulmonary disease (COPD). Acute exacerbation is an important factor in the management of TDL. Therefore, the aim of this study was to investigate the factors associated with acute exacerbations in patients with stable TDL with airflow limitation. METHODS: We evaluated the clinical characteristics, such as lung function, image findings, and serum laboratory findings, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and interleukin (IL)-6, in patients with TDL with chronic airflow limitation (n=94). We evaluated the correlation of these parameters with acute exacerbation. RESULTS: We found that patients with exacerbation were more likely to have bronchiectasis than those without exacerbation (patients with exacerbation, 66.7%; patients without exacerbation, 30.5%; P=0.001). CRP and IL-6 levels were significantly higher in patients with exacerbation than in those without exacerbation (P=0.001 and P<0.001, respectively). Bronchiectasis [OR, 3.248; 95% confidence interval (CI), 1.063-9.928; P=0.039] and elevated IL-6 levels (OR, 1.128; 95% CI, 1.013-1.257; P=0.028) were the most important parameters associated with acute exacerbation in patients with TDL with airflow limitation. CONCLUSIONS: Patients with bronchiectasis and high IL-6 levels may require more intensive treatment to prevent acute exacerbation.
BACKGROUND: Patients with tuberculosis-destroyed lungs (TDLs), with airflow limitation, have clinical characteristics similar to those of patients with chronic obstructive pulmonary disease (COPD). Acute exacerbation is an important factor in the management of TDL. Therefore, the aim of this study was to investigate the factors associated with acute exacerbations in patients with stable TDL with airflow limitation. METHODS: We evaluated the clinical characteristics, such as lung function, image findings, and serum laboratory findings, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and interleukin (IL)-6, in patients with TDL with chronic airflow limitation (n=94). We evaluated the correlation of these parameters with acute exacerbation. RESULTS: We found that patients with exacerbation were more likely to have bronchiectasis than those without exacerbation (patients with exacerbation, 66.7%; patients without exacerbation, 30.5%; P=0.001). CRP and IL-6 levels were significantly higher in patients with exacerbation than in those without exacerbation (P=0.001 and P<0.001, respectively). Bronchiectasis [OR, 3.248; 95% confidence interval (CI), 1.063-9.928; P=0.039] and elevated IL-6 levels (OR, 1.128; 95% CI, 1.013-1.257; P=0.028) were the most important parameters associated with acute exacerbation in patients with TDL with airflow limitation. CONCLUSIONS: Patients with bronchiectasis and high IL-6 levels may require more intensive treatment to prevent acute exacerbation.
Authors: Miguel Á Martínez-García; Javier de Gracia; Monserrat Vendrell Relat; Rosa-Maria Girón; Luis Máiz Carro; David de la Rosa Carrillo; Casilda Olveira Journal: Eur Respir J Date: 2013-11-14 Impact factor: 16.671
Authors: A F Connors; N V Dawson; C Thomas; F E Harrell; N Desbiens; W J Fulkerson; P Kussin; P Bellamy; L Goldman; W A Knaus Journal: Am J Respir Crit Care Med Date: 1996-10 Impact factor: 21.405
Authors: C K Rhee; K H Yoo; J H Lee; M J Park; W J Kim; Y B Park; Y I Hwang; Y S Kim; J Y Jung; J Y Moon; Y K Rhee; H K Park; J H Lim; H Y Park; S W Lee; Y H Kim; S H Lee; H K Yoon; J W Kim; J S Kim; Y K Kim; Y M Oh; S D Lee; H J Kim Journal: Int J Tuberc Lung Dis Date: 2013-01 Impact factor: 2.373
Authors: J J Soler-Cataluña; M A Martínez-García; P Román Sánchez; E Salcedo; M Navarro; R Ochando Journal: Thorax Date: 2005-07-29 Impact factor: 9.139